The startup, which leverages technology to assist chronic kidney disease and end-stage renal disease patients, has wrapped up a $24 million Series A round led by Oak HC/FT.
The bill, known as the ESRD Choice Act (H.R. 5?659), would allow enrollment in the Medicare managed care plans to ESRD patients undergoing dialysis treatment.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Investment driven from Baxter Ventures and Boston Scientific Corporation has brought TVA Medical up by $15 million.